2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss
2012
Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness
Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese Schizophrenia Spectrum Patients Have Significantly Higher 10-Year General Cardiovascular Risk and Vascular Ages than Obese Individuals without Severe Mental Illness. Journal Of The Academy Of Consultation-Liaison Psychiatry 2012, 54: 67-73. PMID: 22664309, PMCID: PMC3435456, DOI: 10.1016/j.psym.2012.03.001.Peer-Reviewed Original ResearchConceptsSevere mental illnessGeneral CVD riskSchizophrenia spectrum patientsVascular ageCVD riskSpectrum patientsNHANES participantsMetabolic riskMental illnessGeneral cardiovascular riskMean vascular ageSystolic blood pressureCardiovascular disease mortalityPrimary care cliniciansHDL cholesterol levelsNutrition Examination SurveyCVD eventsCardiovascular riskObese controlsObese patientsBlood pressureCare cliniciansHypertension treatmentSmoking statusExamination Survey
2008
Successful acamprosate treatment of alcohol dependence in schizophrenia
Tek C, Srihari V, Tek E. Successful acamprosate treatment of alcohol dependence in schizophrenia. Schizophrenia Research 2008, 106: 373. PMID: 18804961, DOI: 10.1016/j.schres.2008.08.010.Peer-Reviewed Original Research
2006
Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder
Srihari VH, Lee TS, Rohrbaugh RM, D'Souza DC. Revisiting cycloid psychosis: A case of an acute, transient and recurring psychotic disorder. Schizophrenia Research 2006, 82: 261-264. PMID: 16442782, DOI: 10.1016/j.schres.2005.11.022.Peer-Reviewed Original ResearchConceptsPsychotic disordersCycloid psychosisTransient psychotic disordersICD-10 categoriesIV-TR criteriaMinimal functional impairmentFavorable prognosisRecurrent psychosisUnknown incidenceDistinct pathophysiologyFunctional impairmentClinical attentionPsychosisDisordersFurther investigationPrognosisPathophysiologyIncidenceCasesImpairment